Form D · Biotechnology
Optimeos Life Sciences, Inc.
Princeton, NJ · CIK 0001819114
Offering snapshot reported Jun 3, 2026 · SEC filing
- Reported sold
- $1M Offering amount: $2M
- Investors reported
- 1 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 22, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 3, 2026 | Initial | $1,000,000 | No comparison | 1 | SEC filing |
| Nov 26, 2024 | Amendment | $2,924,996 | $1,049,992vs Jul 7, 2023 | 5 | SEC filing |
| Jul 7, 2023 | Initial | $1,875,004 | No comparison | 4 | SEC filing |
| Jun 1, 2021 | Initial | $175,000 | No comparison | Not reported | SEC filing |
| Aug 7, 2020 | Initial | $270,000 | No comparison | 3 | SEC filing |
Offering details
- Securities
- Debt, Option to acquire
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-585980
Source: Form D, filed Jun 3, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Benjamin Doranz | Director |
| Shahram Hejazi | Director, Executive |
| Shahram Hejazi, Ph D | Director, Executive |
| Robert K Prud'homme | Director |
| Robert K. Prud'homme, Ph D | Director |
| Jason Smith | Director |
| Jason Smith, Ph D | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
174 Nassau Street, Suite 334
Princeton, NJ, 08542
Princeton, NJ, 08542